Roger Pomerantz, ContraFect CEO (via X-Vax)
July 14, 2022 10:47 AM EDTUpdated 11:05 AM
R&D

Up­dat­ed: Con­tra­Fect to ter­mi­nate PhI­II MR­SA an­tibi­ot­ic tri­al — stock cap­sizes

Lei Lei Wu

News Reporter

One year af­ter BAR­DA backed Con­tra­Fect’s MR­SA treat­ment, the Yonkers, NY-based biotech said Wednes­day it will stop its Phase III tri­al of the as­set ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times